Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 34

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 34
---
. Limited respectively, with 4.99% of the shares reserved
for its employee share plan.

Currently, we conduct the
majority of our operations through the following subsidiaries: Aptorum Therapeutics Limited, Nativus Life Sciences Limited, Aptorum Medical
Limited and Aptorum Innovations Holding Pte. Limited. All investments into our company are into the parent company, Aptorum Group Limited;
you may never hold direct equity interests in our subsidiaries or VIEs.

Prior to March 2017, the Company
had pursued passive healthcare related investments in early stage companies primarily in the United States. However, we have since ceased
pursuing further passive investment operations and intend to exit all such portfolio investments over an appropriate timeframe to focus
resources on our current business.

On December 30, 2020, Aptorum
Innovations Holding Limited, or AIHL, one of the Company’s wholly-owned subsidiaries, entered into an Evaluation Agreement with
Illumina Inc (“Illumina”). Pursuant to the agreement, AIHL will evaluate the data and performance of Illumina’s sequencing
technology based on the workflow of AIHL’s molecular rapid pathogen identification and detection diagnostics technology (“RPIDD”),
at AIHL’s Singapore based evaluation site.

Corporate Information

Our principal executive office
is located at 17 Hanover Square, London W1S 1BN, United Kingdom. Our telephone number is +44 20 80929299.

Our website is www.aptorumgroup.com.
The information on our website is not part of this prospectus.

We make available free
of charge through our website our annual report on Form 20-F, current reports on Form 6-K, and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. The information contained in, or that can be accessed through,
our website is not part of this prospectus or any prospectus supplement.

<div align='center'>2</div>

ABOUT THE SECONDARY OFFERING The secondary offering of this prospectus relates to the offer and resale by the Selling Shareholders of an aggregate of 540,540 Class A Ordinary Shares, all of which are issuable upon the exercise of 540,540 Selling Shareholder Warrants. All of the Class A Ordinary Shares